NanoSphere Health Sciences Inc. (NSHSF)
USD 0.04
(-60.0%)
USD 0.04
(-60.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 17.88 Thousand USD | -70.22% |
| 2022 | 60.04 Thousand USD | -54.68% |
| 2021 | 132.51 Thousand USD | 140.11% |
| 2020 | 55.18 Thousand USD | -83.46% |
| 2019 | 333.72 Thousand USD | -74.7% |
| 2018 | 1.31 Million USD | -65.72% |
| 2017 | 3.84 Million USD | 275.93% |
| 2016 | 1.02 Million USD | 463.77% |
| 2015 | 181.58 Thousand USD | 90.36% |
| 2014 | 95.38 Thousand USD | -0.51% |
| 2013 | 95.88 Thousand USD | -98.61% |
| 2012 | 6.87 Million USD | 12.21% |
| 2011 | 6.13 Million USD | 22.61% |
| 2010 | 5 Million USD | 891.13% |
| 2009 | 504.51 Thousand USD | 55.16% |
| 2008 | 325.15 Thousand USD | -95.82% |
| 2007 | 7.77 Million USD | 2564.4% |
| 2006 | 291.86 Thousand USD | -8.49% |
| 2005 | 318.94 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 32.99 Thousand USD | 84.34% |
| 2024 Q1 | 17.9 Thousand USD | 0.13% |
| 2023 FY | 17.88 Thousand USD | -70.22% |
| 2023 Q1 | 39.17 Thousand USD | -34.75% |
| 2023 Q2 | 33.32 Thousand USD | -14.93% |
| 2023 Q3 | 19.02 Thousand USD | -42.93% |
| 2023 Q4 | 17.88 Thousand USD | -6.0% |
| 2022 Q2 | 93.53 Thousand USD | -28.2% |
| 2022 FY | 60.04 Thousand USD | -54.68% |
| 2022 Q4 | 60.04 Thousand USD | -7.55% |
| 2022 Q3 | 64.95 Thousand USD | -30.56% |
| 2022 Q1 | 130.26 Thousand USD | -1.7% |
| 2021 FY | 132.51 Thousand USD | 140.11% |
| 2021 Q2 | 7167.00 USD | -76.72% |
| 2021 Q3 | 150.95 Thousand USD | 2006.21% |
| 2021 Q1 | 30.78 Thousand USD | -44.23% |
| 2021 Q4 | 132.51 Thousand USD | -12.21% |
| 2020 Q4 | 55.18 Thousand USD | -58.18% |
| 2020 Q1 | 246.59 Thousand USD | -26.11% |
| 2020 Q2 | 164.12 Thousand USD | -33.44% |
| 2020 Q3 | 131.95 Thousand USD | -19.6% |
| 2020 FY | 55.18 Thousand USD | -83.46% |
| 2019 Q1 | 2.13 Million USD | 62.14% |
| 2019 FY | 333.72 Thousand USD | -74.7% |
| 2019 Q2 | 1.74 Million USD | -18.43% |
| 2019 Q3 | 1.44 Million USD | -17.01% |
| 2019 Q4 | 333.72 Thousand USD | -76.95% |
| 2018 Q4 | 1.31 Million USD | -33.38% |
| 2018 FY | 1.31 Million USD | -65.72% |
| 2018 Q3 | 1.98 Million USD | -8.34% |
| 2018 Q2 | 2.16 Million USD | -23.8% |
| 2018 Q1 | 2.83 Million USD | -26.32% |
| 2017 FY | 3.84 Million USD | 275.93% |
| 2017 Q3 | 1.32 Million USD | 70.87% |
| 2017 Q2 | 774.96 Thousand USD | -14.44% |
| 2017 Q1 | 905.74 Thousand USD | -11.52% |
| 2017 Q4 | 3.84 Million USD | 190.62% |
| 2016 FY | 1.02 Million USD | 463.77% |
| 2016 Q1 | 173.23 Thousand USD | -4.6% |
| 2016 Q3 | 1.09 Million USD | 693.78% |
| 2016 Q2 | 137.37 Thousand USD | -20.7% |
| 2016 Q4 | 1.02 Million USD | -6.12% |
| 2015 Q1 | 85.12 Thousand USD | -10.76% |
| 2015 Q3 | 190.74 Thousand USD | 282.8% |
| 2015 Q4 | 181.58 Thousand USD | -4.8% |
| 2015 FY | 181.58 Thousand USD | 90.36% |
| 2015 Q2 | 49.82 Thousand USD | -41.46% |
| 2014 Q3 | 128.88 Thousand USD | 111.48% |
| 2014 FY | 95.38 Thousand USD | -0.51% |
| 2014 Q4 | 95.38 Thousand USD | -25.99% |
| 2014 Q1 | 63.26 Thousand USD | -34.01% |
| 2014 Q2 | 60.94 Thousand USD | -3.67% |
| 2013 Q4 | 95.88 Thousand USD | -92.3% |
| 2013 Q3 | 1.24 Million USD | -22.05% |
| 2013 Q2 | 1.59 Million USD | -74.6% |
| 2013 Q1 | 6.29 Million USD | -8.57% |
| 2013 FY | 95.88 Thousand USD | -98.61% |
| 2012 Q3 | 3.92 Million USD | -10.28% |
| 2012 Q1 | 5.4 Million USD | -11.9% |
| 2012 FY | 6.87 Million USD | 12.21% |
| 2012 Q4 | 6.87 Million USD | 75.37% |
| 2012 Q2 | 4.37 Million USD | -19.05% |
| 2011 Q2 | 13.23 Million USD | 120.15% |
| 2011 Q3 | 12.52 Million USD | -5.42% |
| 2011 FY | 6.13 Million USD | 22.61% |
| 2011 Q1 | 6.01 Million USD | 20.27% |
| 2011 Q4 | 6.13 Million USD | -51.04% |
| 2010 FY | 5 Million USD | 891.13% |
| 2010 Q3 | 395.47 Thousand USD | -7.75% |
| 2010 Q1 | 493.13 Thousand USD | -2.26% |
| 2010 Q4 | 5 Million USD | 1164.43% |
| 2010 Q2 | 428.7 Thousand USD | -13.06% |
| 2009 Q2 | 225.94 Thousand USD | -14.21% |
| 2009 Q1 | 263.36 Thousand USD | -19.0% |
| 2009 FY | 504.51 Thousand USD | 55.16% |
| 2009 Q3 | 474.59 Thousand USD | 110.05% |
| 2009 Q4 | 504.51 Thousand USD | 6.3% |
| 2008 Q3 | 515.61 Thousand USD | -92.68% |
| 2008 Q1 | 7.03 Million USD | -9.48% |
| 2008 Q4 | 325.15 Thousand USD | -36.94% |
| 2008 FY | 325.15 Thousand USD | -95.82% |
| 2008 Q2 | 7.04 Million USD | 0.09% |
| 2007 Q1 | 360.08 Thousand USD | 23.37% |
| 2007 Q3 | 8.4 Million USD | 2.19% |
| 2007 Q4 | 7.77 Million USD | -7.48% |
| 2007 FY | 7.77 Million USD | 2564.4% |
| 2007 Q2 | 8.22 Million USD | 2184.27% |
| 2006 Q3 | 311.45 Thousand USD | -1.18% |
| 2006 Q1 | 313.43 Thousand USD | -1.73% |
| 2006 FY | 291.86 Thousand USD | -8.49% |
| 2006 Q4 | 291.86 Thousand USD | -6.29% |
| 2006 Q2 | 315.17 Thousand USD | 0.56% |
| 2005 FY | 318.94 Thousand USD | 0.0% |
| 2005 Q3 | 349.26 Thousand USD | 0.0% |
| 2005 Q4 | 318.94 Thousand USD | -8.68% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -674.026% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.087% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.831% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 96.762% |
| Rebus Holdings, Inc. | 5000.00 USD | -257.6% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.986% |
| Qrons Inc. | 420.00 USD | -4157.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 97.68% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.936% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 96.279% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.85% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.954% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.752% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 76.583% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.983% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 98.751% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 75.292% |
| Mesoblast Limited | 667.9 Million USD | 99.997% |
| Marizyme, Inc. | 22.01 Million USD | 99.919% |
| Genus plc | 1.02 Billion USD | 99.998% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 98.684% |
| Pharming Group N.V. | 462.85 Million USD | 99.996% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.46% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 96.417% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 97.148% |
| ContraFect Corporation | 20.67 Million USD | 99.914% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 95.42% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 95.322% |
| IMV Inc. | 31.33 Million USD | 99.943% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.569% |
| MultiCell Technologies, Inc. | 126.22 USD | -14065.742% |
| ONE Bio Corp. | 70.08 Million USD | 99.974% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 98.097% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.986% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 95.858% |
| Q BioMed Inc. | 3.51 Million USD | 99.491% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.949% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 93.157% |
| Biomind Labs Inc. | 73.81 Thousand USD | 75.779% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.996% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 98.766% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.94% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.349% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 97.399% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.313% |
| GB Sciences, Inc. | 103.44 Thousand USD | 82.715% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.271% |
| HST Global, Inc. | 1526.00 USD | -1071.691% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 98.19% |
| Halberd Corporation | 10.13 Thousand USD | -76.488% |
| Enzolytics Inc. | 361.7 Million USD | 99.995% |
| Agentix Corp. | 261.39 Thousand USD | 93.16% |
| Resverlogix Corp. | 8.11 Million USD | 99.78% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.048% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.963% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 97.205% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 21.514% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.8% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.758% |
| Zenith Capital Corp. | 7410.00 USD | -141.296% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.999% |
| Ember Therapeutics, Inc. | 184.00 USD | -9617.391% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 94.444% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 93.159% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 98.073% |
| Kadimastem Ltd | 2.3 Million USD | 99.224% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.409% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.966% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.877% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 68.683% |
| LadRx Corporation | 2.3 Million USD | 99.225% |
| Cell Source, Inc. | 195.17 Thousand USD | 90.839% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 94.944% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 94.944% |
| NovAccess Global Inc. | 62.24 Thousand USD | 71.276% |
| Affymax, Inc. | 7.44 Million USD | 99.76% |
| Itoco Inc. | 1.4 Million USD | 98.723% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 81.308% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 83.132% |
| Mobile Lads Corp. | 52.00 USD | -34284.615% |
| CytoDyn Inc. | 11.13 Million USD | 99.839% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 87.494% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 95.362% |
| SYBLEU INC | 330.46 Thousand USD | 94.589% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 95.633% |
| International Stem Cell Corporation | 5.39 Million USD | 99.668% |
| Bioxytran, Inc. | 137.63 Thousand USD | 87.009% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.881% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.892% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 77.367% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 97.932% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.762% |
| Neutra Corp. | 2851.00 USD | -527.148% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.945% |
| PureTech Health plc | 693.97 Million USD | 99.997% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.778% |
| IXICO plc | 15.84 Million USD | 99.887% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.784% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.983% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.995% |